Fireside Chat Webcast Available
SAN DIEGO and GAINESVILLE, Ga., Dec. 02, 2021 (GLOBE NEWSWIRE) — Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that its chief executive officer, David Enloe, will participate in a fireside chat as part of the Stephens Annual Investment Conference | NASH2021. Details for the fireside chat are as follows:
About Recro
Recro (NASD: REPH) is a bi-coastal contract development and manufacturing organization (CDMO) with capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus in the area of small molecules. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market.
In addition to our experience in handling DEA controlled substances and developing and manufacturing modified-release dosage forms, Recro has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 145,000 square feet, in Gainesville, Georgia and San Diego, California.
For more information about Recro’s CDMO solutions, visit recrocdmo.com.
CONTACT: Contacts Stephanie Diaz (Investors) Vida Strategic Partners (415) 675-7401 sdiaz@vidasp.com Tim Brons (Media) Vida Strategic Partners (415) 675-7402 tbrons@vidasp.com Ryan D. Lake (CFO) Recro (770) 531-8365 ryan.lake@recroCDMO.com
DALLAS, March 26, 2025 /PRNewswire/ -- Ventra Health ("Ventra"), a leading business solutions provider for facility-based…
MILPITAS, Calif., March 26, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE:…
BOULDER, Colo., March 26, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle…
A global collaboration agreement has been signed for the development and commercialization of a Granzyme…
MARPAI EXHIBITS STRONG, ONGOING FINANCIAL IMPROVEMENT TAMPA, Fla., March 26, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai"…
WINDSOR, Conn., March 26, 2025 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the election…